Home/Pipeline/EIK-004

EIK-004

Undisclosed

DiscoveryActive

Key Facts

Indication

Undisclosed

Phase

Discovery

Status

Active

Company

Eikon Therapeutics

About Eikon Therapeutics

Eikon Therapeutics' mission is to pioneer a new paradigm in drug discovery by directly observing the dynamic behavior of proteins in living cells, a field it terms 'dynamic biology.' The company has successfully built and scaled its proprietary platform, transitioned to a public company (NASDAQ: EIKN), and advanced a pipeline of five disclosed programs. Its strategy is to leverage its unique observational biology platform to identify and prosecute novel, high-value targets with the potential for first-in-class or best-in-class therapeutics.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 1	Bolt Biotherapeutics	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
Amgen Collaboration Program	Xeris Biopharma	Pre-clinical	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active